Philip Friedlander, MD, PhD
Cancer (Oncology), Hematology-Oncology
Dr. Friedlander received medical school training at Columbia University where he obtained his M.D. and Ph.D. degree in Biology. He remained at Columbia Presbyterian Medical Center to complete his postdoctoral training in Internal Medicine and subsequently completed a clinical fellowship in Medical Oncology at Memorial Sloan Kettering Cancer Center. He then joined the faculty of the Dana Farber Cancer Institute/Brigham and Women’s Hospital as an attending physician within the Melanoma and Cutaneous Oncology Programs and as an Instructor of Medicine at Harvard Medical School.
His clinical interests include the development of targeted therapies and immunotherapies for patients with melanoma, merkel cell carcinoma, advanced cutaneous squamous cell carcinoma, basal cell carcinoma, and sebaceous gland tumors. At the Dana Farber Cancer Institute he acted as a principal investigator testing novel therapeutic approaches for melanoma including PARP inhibition, hsp90 inhibition, anti-apoptotic approaches, and immune modulatory and anti-CTLA4 based strategies. He investigated in non-melanoma skin cancers novel therapeutic strategies such as hedgehog signaling pathway inhibition in advanced basal cell carcinoma.
As a member of the Division of Hematology/Medical Oncology and as the Director of the Melanoma Medical Oncology Program at Mount Sinai, he will be caring for patients with cutaneous malignancies and continue working to develop collaborative translational and basic science projects and treatments for patients with cutaneous malignancies.
In the News:
Watch Dr. Friedlander discuss a new FDA approved treatment (Erivedge) for Basal Cell Carcinoma:
KTVX-TV (ABC/Salt Lake City, Utah)
KRNV-TV (NBC/Reno, Nevada)
WNAV-AM (Baltimore, Maryland)
- Mount Sinai Beth Israel
- Mount Sinai Queens
- The Mount Sinai Hospital
- Mount Sinai Morningside and Mount Sinai West